Feng Li

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Mesenchymal Stem Cells

Top Venues

Disease markers

Current cancer drug targets

This page only lists publications with an associated author ORCID identifier.

Publications

Zhuanxia Dong, Zefeng Yang, Jing Ren, Feng Li, Yusheng Wang, Yuanyuan Yu
Envafolimab Inhibits the Growth of Gastric Cancer Cells with Low PD-L1 Expression through the DDX20/NF-κB/TNF-α Signaling Pathway. Current cancer drug targets (2024)
Weina Li, Guohui Han, Feng Li, Peng Bu, Yating Hao, Li Huang, Xiangdong Bai
Cancer cell-derived exosomal miR-20a-5p inhibits CD8 + T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer. Cancer science 115 (2) (2023)
Weina Li, Guohui Han, Feng Li, Peng Bu, Yating Hao, Li Huang, Xiangdong Bai
Cancer cell-derived exosomal miR-20a-5p inhibits CD8 + T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer. Cancer science 115 (2) (2023)
Weina Li, Guohui Han, Feng Li, Peng Bu, Yating Hao, Li Huang, Xiangdong Bai
Cancer cell-derived exosomal miR-20a-5p inhibits CD8 + T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer. Cancer science 115 (2) (2023)
Weina Li, Guohui Han, Feng Li, Peng Bu, Yating Hao, Li Huang, Xiangdong Bai
Cancer cell-derived exosomal miR-20a-5p inhibits CD8 + T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer. Cancer science (2023)
Jing Cui, Nanjing Cao, Guochao Wang, Fuhua Wang, Bin Yang, Jian Wang, Yongqiang Lv, Yunqing Chen, Feng Li
HuR Promotes the Progression of Gastric Cancer through Mediating CDC5L Expression. Disease markers 2022 (2022)
Gang Ti, Zongliang Guo, Lili Li, Yongqiang Lv, Bin Yang, Jian Wang, Rui Guo, Yunqing Chen, Debin Meng, Feng Li
miR-33a-5p Targets RAP2A to Mediate the Sensitivity of Gastric Cancer Cells to 5-FU. Disease markers 2022 (2022)